Company
Senior Executive Officers
Board of Directors
Ethics Advisory Board
Careers
Glossary
Contact Us
Technology
Regenerative Medicine
Blastomere Program
Cellular Reprogramming
Stem Cell Differentiation
Intellectual Property
Pipeline
Overview
Potential Markets
Myoblast Program
RPE Program
Hemangioblast (HG) Cell Program
News and Media
ACT Corporate Overview
Press Releases
Conference Presentations
Media Gallery
Media Contact
Safe Medication from Canadian Pharmacies
Investors
Investors Overview
Research Reports
Corporate Governance
Committee Charters
Whistleblower Hotline
Sitemap
Page 2 of 5 :
Previous
:
Next
Posts
Category:
Press Releases
(continued)
Advanced Cell Technology Announces Formation of Institutional Review Board and Commencement of SCNT Program
Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials
Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources
Advanced Cell Technology Announces New Board Member
Advanced Cell Technology Announces Proposed Financing
Advanced Cell Technology Announces the Promotion of Dr. Robert Lanza to Chief Scientific Officer
Advanced Cell Technology Announces Use of Nuclear Transfer Technology for Successful Generation of Human Embryonic Stem Cells
Advanced Cell Technology Announces Use of Nuclear Transfer Technology for Successful Generation of Human Embryonic Stem Cells
Advanced Cell Technology Appoints Eddy Anglade M.D. Executive Vice President of Clinical Development
Advanced Cell Technology Appoints Mr. William Caldwell, Iv As Chief Executive Officer And Appoints Dr. Michael West As Chairman, President And Chief Scientific Officer
Advanced Cell Technology Awarded Broad Patent For Production of Retinal Pigment Epithelial Cells
Advanced Cell Technology Demonstrates Efficient Generation of Functional Hepatocytes (Liver cells) From Human Embryonic Stem Cells
Advanced Cell Technology Elects Not to Complete Reverse Split
Advanced Cell Technology Expands Somatic Cell Nuclear Transfer (Cloning) and Cellular Reprogramming Intellectual Property Portfolio
Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease
Advanced Cell Technology Files Preliminary Proxy Statement with Securities and Exchange Commission
Advanced Cell Technology Provides Single Blastomere Technology To CHA Bio & Diostech Co., Ltd.
Advanced Cell Technology Raises $17.75 Million through Private Placement of Convertible Notes and Warrants
Advanced Cell Technology Reaches Agreement with Spanish Government to Clone First Extinct Animal
Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
Advanced Cell Technology Receives Federal Grant for Nearly $1 Million
Advanced Cell Technology Reports Visual Function Rescue in Animals Utilizing Human Embryonic Stem Cell-Derived Retinal Cells
Advanced Cell Technology Secures New $35 Million Funding Commitment from Lincoln Park Capital
Advanced Cell Technology to Deliver the Keynote Address at the Strategies for Engineered Negligible Senescence (SENS) Conference
Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
Advanced Cell Technology To Present in the Regenerative Medicine Insight Track at the Biotech Showcase™ 2012 in San Francisco
Advanced Cell Technology, Inc. (ACT) today announced publication of its research on human somatic cell nuclear transfer and parthenogenesis.
Advanced Cell Technology, Inc. Enters into License Agreement with Pharming Group N.V.
Advanced Cell Technology‘s RPE Cells Granted Orphan Drug Status from FDA for Treatment of Stargardt’s Macular Dystrophy
Advanced Cell Technology’s Dr. Robert Lanza Testifies Before U.S. Senate Subcommittee
Advanced Cell Technology’s Studies to Support Phase I Multicenter Trial of Patients with Stargardt’s Macular Dystrophy Demonstrate Excellent Safety Profile
Advanced Cell Technologys Study Published in Leading Hematology Journal
Dr. Robert Lanza of Advanced Cell Technology Testifies Before Senate Subcommittee
First Derivation Of Human Embryonic Stem Cells Without Exposure To Cell Feeders
Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration
New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties
NIH Approves Advanced Cell Technology's Stem Cell Line for Federal Funding
Patients with Better Vision to be Enrolled in ACT's Clinical Trials for Macular Degeneration
Precursor Cells Generated From Human Embryonic Stem Cells Show Ability to Repair Vascular Damage in Animals
RESEARCHERS REPORT FIRST EVIDENCE THAT NUCLEAR TRANSPLANTATION (“THERAPEUTIC CLONING”) CAN ELIMINATE TISSUE REJECTION
RESEARCHERS REPORT FIRST EVIDENCE THAT NUCLEAR TRANSPLANTATION (“THERAPEUTIC CLONING”) CAN ELIMINATE TISSUE REJECTION
Somatic Cell Nuclear Transfer Gives Old Animals Youthful Immune Cells
WiCell Research Institute and Advanced Cell Technology Offer to Distribute New Stem Cell Lines to U.S. Researchers
Category:
Recent News Item
Bush’s Policy Stopped U.S. Gaining Stem-Cell Lead
Ethics Advisory Board for Advanced Cell Technology, Inc.: “Human Embryonic Stem Cell Lines Derived from Single Blastomeres”
Human Stem Cells Help Blinded Rats: Study
Next Step in Stem Cells: Human tests
Related News: Heart Myoblast Cell Injection
Reprogramming Complicates Stem Cell Debate
